Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 3—March 2023
Dispatch

Emergomyces pasteurianus in Man Returning to the United States from Liberia and Review of the Literature

Jacob PierceComments to Author , Sadia Sayeed, Christopher D. Doern, and Alexandra L. Bryson
Author affiliation: Virginia Commonwealth University Medical Center, Richmond, Virginia, USA

Main Article

Table 1

MIC/MEC (μg/mL)Antimicrobial susceptibility of antifungal agents for Emergomyces pasteurianus isolate from a patient returning to the United States from Liberia and reported cases from the literature*

Case (ref) AMB MICA ANID FLC ITC VOR POS ISA 5-FC
This study
 0.25
 0.03
 <0.015
 >64
 0.06
 0.25
 0.25
 1.0
 >64
1 (8)
 0.031
 0.031
 0.5
 >64
 0.125
 0.25
 0.125
 2.0
 NA
2 (9)
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
3 (4)
 1.0
 0.05
 NA
 2.0
 0.125
 0.25
 0.125
 NA
 NA
4 (10)
 0.125
 0.063
 0.0031
 >64
 0.25
 0.25
 0.063
 1.0
 NA
5 (11)
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
6 (5)
 0.031
 <0.008
 NA
 64
 0.063
 0.25
 0.063
 1.0
 NA
7 (5)
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
8 (12)
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
9 (13)
 1.0
 0.5†
 NA
 4.0
 0.125
 0.25
 0.125
 NA
 NA
10 (14) NA NA NA NA NA NA NA NA NA

*Values are MICs (μg/mL), except as indicated. 5-FC, 5-fluorocytosine; AMB, amphotericin B; ANID, anidulafungin; FLC, fluconazole; ISA, isavuconazole; ITC, itraconazole; MICA, micafungin; POS, posaconazole; ref, reference; VOR, voriconazole. †Caspofungin minimal effective concentration.

Main Article

References
  1. Schwartz  IS, Kenyon  C, Feng  P, Govender  NP, Dukik  K, Sigler  L, et al. 50 years of Emmonsia disease in humans: the dramatic emergence of a cluster of novel fungal pathogens. PLoS Pathog. 2015;11:e1005198. DOIPubMedGoogle Scholar
  2. Dukik  K, Muñoz  JF, Jiang  Y, Feng  P, Sigler  L, et al. Novel taxa of thermally dimorphic systemic pathogens in the Ajellomycetaceae (Onygenales). 2018;60:296–309.
  3. Samaddar  A, Sharma  A. Emergomycosis, an emerging systemic mycosis in immunocompromised patients: current trends and future prospects. Front Med (Lausanne). 2021;8:670731. DOIPubMedGoogle Scholar
  4. Malik  R, Capoor  MR, Vanidassane  I, Gogna  A, Singh  A, Sen  B, et al. Disseminated Emmonsia pasteuriana infection in India: a case report and a review. Mycoses. 2016;59:127–32. DOIPubMedGoogle Scholar
  5. Gast  KB, van der Hoeven  A, de Boer  MGJ, van Esser  JWJ, Kuijper  EJ, Verweij  JJ, et al. Two cases of Emergomyces pasteurianus infection in immunocompromised patients in the Netherlands. Med Mycol Case Rep. 2019;24:5–8. DOIPubMedGoogle Scholar
  6. Dukik  K, Al-Hatmi  AMS, Curfs-Breuker  I, Faro  D, de Hoog  S, Meis  JF. Antifungal susceptibility of emerging dimorphic pathogens in the family Ajellomycetaceae. Antimicrob Agents Chemother. 2017;62:e01886–17.PubMedGoogle Scholar
  7. Maphanga  TG, Britz  E, Zulu  TG, Mpembe  RS, Naicker  SD, Schwartz  IS, et al. In vitro antifungal susceptibility of yeast and mold phases of isolates of dimorphic fungal pathogen Emergomyces africanus (formerly Emmonsia sp.) from HIV-infected South African patients. J Clin Microbiol. 2017;55:1812–20. DOIPubMedGoogle Scholar
  8. Gori  S, Drouhet  E, Guého  E, Huerre  MR, Lofaro  A, Parenti  M, et al. Cutaneous disseminated mycosis in a patient with AIDS due to a new dimorphic fungus [in French]. J Mycol Med. 1998;8:57–63.
  9. Pelegrín  I, Ayats  J, Xiol  X, Cuenca-Estrella  M, Jucglà  A, Boluda  S, et al. Disseminated adiaspiromycosis: case report of a liver transplant patient with human immunodeficiency infection, and literature review. Transpl Infect Dis. 2011;13:507–14. DOIPubMedGoogle Scholar
  10. Feng  P, Yin  S, Zhu  G, Li  M, Wu  B, Xie  Y, et al. Disseminated infection caused by Emmonsia pasteuriana in a renal transplant recipient. J Dermatol. 2015;42:1179–82. DOIPubMedGoogle Scholar
  11. Tang  XH, Zhou  H, Zhang  XQ, Han  JD, Gao  Q. Cutaneous disseminated emmonsiosis due to Emmonsia pasteuriana in a patient with cytomegalovirus enteritis. JAMA Dermatol. 2015;151:1263–4. DOIPubMedGoogle Scholar
  12. Rooms  I, Mugisha  P, Gambichler  T, Hadaschik  E, Esser  S, Rath  PM, et al. Disseminated emergomycosis in a person with HIV infection, Uganda. Emerg Infect Dis. 2019;25:1750–1. DOIPubMedGoogle Scholar
  13. Capoor  MR, Mishra  N, Kolte  S, Singla  G, Gogna  A, Rudramurthy  S, et al. Disseminated Emergomyces pasteurianus infection in India: a case report and a review. Mycopathologia. 2020;185:193–200.PubMedGoogle Scholar
  14. Chik  KK, To  WK. Autochthonous Emergomyces pasteurianus pneumonia in an immunocompromised patient in Hong Kong: a case report. Hong Kong Med J. 2020;26:446–8. DOIPubMedGoogle Scholar

Main Article

Page created: January 12, 2023
Page updated: February 20, 2023
Page reviewed: February 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external